RemeGen Co., Ltd. (9995.HK) stock analysis

In our weekly check, RemeGen Co., Ltd. is graded B (A to F). Of 24 checks on debt, profit, cash flow and trend: 16 pass, warnings: 3, red flags: 5.

About RemeGen Co., Ltd.

RemeGen Co., Ltd. is a Healthcare company (Biotechnology) based in China, listed on HKSE as 9995.HK.

What our checks show for 9995.HK

Red flags

• The gross margin fell by 3.1 points, to 92.2%: costs are rising faster than prices.
• Analysts expect revenue to shrink about 14.7% a year.
• Analysts expect the net margin to shrink by 55.3 points from today's 78.8%.
• The price swings a lot: 59.9% annual volatility. Expect large ups and downs.
• The stock has fallen as much as 93% from a peak. Would you have held through that?

Warning signs

• Operating cash flow is only 0.61x net profit: part of the reported profit does not arrive as cash.
• Analysts expect earnings per share to shrink about 48.2% a year.
• The stock is still below its previous peak.

Strengths

• Debt is low: 0.03x equity.
• Operating profit covers interest 156 times over.
• The net margin rose by 59.3 points over 5 years, to 78.8%.
• Revenue grew 121% a year over the last 3 years.
• Earnings per share grew 83.6% a year over the last 3 years.
• The company keeps 78.8% of its revenue as net profit.

Similar companies

GMAB · 1530.HK · ONC · RVMDW · LONN.SW · ROIV

Questions

What grade does RemeGen Co., Ltd. (9995.HK) have?

In our weekly check, RemeGen Co., Ltd. is graded B (A to F). Of 24 checks on debt, profit, cash flow and trend: 16 pass, warnings: 3, red flags: 5. The grade is a risk check, not a buy or sell recommendation.

What are the main risks of 9995.HK stock?

This week's biggest flags for RemeGen Co., Ltd.: Gross margin falling, Weak revenue forecast, Margins expected to shrink. In total 8 of 24 checks show a warning or a red flag.

What does RemeGen Co., Ltd. do?

RemeGen Co., Ltd. is a Healthcare company (Biotechnology) based in China, listed on HKSE as 9995.HK.

The grade is a risk check, not a price forecast, and not investment advice. In our 10-year test (S&P 500, 2016-2026), stocks we graded A or B fell more than 30% 2-3 times less often than D or F, without a lower average return.

Updated 2026-10-31

Open the full analysis